They have shown efficacy in sparing OCS, reducing exacerbation rates, and improving asthma control and lung function [5,6]: anti-IgE (Omalizumab), anti-IL-5/Rα (Mepolizumab, Reslizumab, and Benralizumab), and anti-IL-4Rα (Dupilumab). Here, IL5 is linked to asthma.